A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07579208
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • NK Cells — DRUG
    Given by Ommaya Reservoir
  • NK Cells — DRUG
    Given by IV

Study Details

To find the best method of administering NK cells in patients with recurrent glioblastoma.

Key Dates

First listed
May 12, 2026
Start date
Aug 21, 2026
Status verified
Aug 2026
Primary completion
Jul 30, 2028
Completion
Jul 30, 2030

Study Design

Enrollment
36 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arm 1 Intra-tumoral
    Will receive the NK cells as an intra-tumoral administration
  • Experimental: Arm 2 Intra-Ventricular
    Will receive the NK cells as an intra-arterial administration
  • Experimental: Arm 3 Intra-arterial
    Will receive the NK cells as an intra-arterial administration .

Primary Outcome Measure

Safety and adverse events (AEs). [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030
Chibawany Ene, MD
[email protected]
713-792-2400
Chibawanye Ene, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

Nationwide
Brain cancer trialsOncology trialsNeuro-oncology trials
By condition
Brain cancer
By specialty
OncologyNeuro-oncology
By research site
MD Anderson Cancer Center· Houston, TX

Related Studies